BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11259574)

  • 1. In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist.
    Birke FW; Meade CJ; Anderskewitz R; Speck GA; Jennewein HM
    J Pharmacol Exp Ther; 2001 Apr; 297(1):458-66. PubMed ID: 11259574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel compounds that interact with both leukotriene B4 receptors and vanilloid TRPV1 receptors.
    McHugh D; McMaster RS; Pertwee RG; Roy S; Mahadevan A; Razdan RK; Ross RA
    J Pharmacol Exp Ther; 2006 Feb; 316(2):955-65. PubMed ID: 16207832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studies.
    Jackson WT; Froelich LL; Boyd RJ; Schrementi JP; Saussy DL; Schultz RM; Sawyer JS; Sofia MJ; Herron DK; Goodson T; Snyder DW; Pechous PA; Spaethe SM; Roman CR; Fleisch JH
    J Pharmacol Exp Ther; 1999 Jan; 288(1):286-94. PubMed ID: 9862783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. cDNA cloning and characterization of guinea-pig leukotriene B4 receptor.
    Masuda K; Yokomizo T; Izumi T; Shimizu T
    Biochem J; 1999 Aug; 342 ( Pt 1)(Pt 1):79-85. PubMed ID: 10432303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia.
    Bäck M; Bu DX; Bränström R; Sheikine Y; Yan ZQ; Hansson GK
    Proc Natl Acad Sci U S A; 2005 Nov; 102(48):17501-6. PubMed ID: 16293697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The in vitro and in vivo pharmacologic activity of the potent and selective leukotriene B4 receptor antagonist CP-105696.
    Showell HJ; Pettipher ER; Cheng JB; Breslow R; Conklyn MJ; Farrell CA; Hingorani GP; Salter ED; Hackman BC; Wimberly DJ
    J Pharmacol Exp Ther; 1995 Apr; 273(1):176-84. PubMed ID: 7714764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of leukotriene B4-induced CD11B/CD18 (Mac-1) expression by BIIL 284, a new long acting LTB4 receptor antagonist, in patients with rheumatoid arthritis.
    Alten R; Gromnica-Ihle E; Pohl C; Emmerich J; Steffgen J; Roscher R; Sigmund R; Schmolke B; Steinmann G
    Ann Rheum Dis; 2004 Feb; 63(2):170-6. PubMed ID: 14722206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelium-dependent vascular responses induced by leukotriene B4.
    Bäck M; Sakata K; Qiu H; Haeggström JZ; Dahlén SE
    Prostaglandins Other Lipid Mediat; 2007 May; 83(3):209-12. PubMed ID: 17481557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cloning and characterization of rat leukotriene B(4) receptor.
    Toda A; Yokomizo T; Masuda K; Nakao A; Izumi T; Shimizu T
    Biochem Biophys Res Commun; 1999 Sep; 262(3):806-12. PubMed ID: 10471406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958.
    Hawkinson JE; Szoke BG; Garofalo AW; Hom DS; Zhang H; Dreyer M; Fukuda JY; Chen L; Samant B; Simmonds S; Zeitz KP; Wadsworth A; Liao A; Chavez RA; Zmolek W; Ruslim L; Bova MP; Holcomb R; Butelman ER; Ko MC; Malmberg AB
    J Pharmacol Exp Ther; 2007 Aug; 322(2):619-30. PubMed ID: 17470643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist with oral antiinflammatory activity.
    Daines RA; Chambers PA; Foley JJ; Griswold DE; Kingsbury WD; Martin LD; Schmidt DB; Sham KK; Sarau HM
    J Med Chem; 1996 Sep; 39(19):3837-41. PubMed ID: 8809171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressive effect of leukotriene B(4) receptor antagonist in vitro.
    Morita H; Takeda K; Yagita H; Okumura K
    Biochem Biophys Res Commun; 1999 Oct; 264(2):321-6. PubMed ID: 10529362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo pharmacological characterization of SB 201993, an eicosanoid-like LTB4 receptor antagonist with anti-inflammatory activity.
    Sarau HM; Foley JJ; Schmidt DB; Martin LD; Webb EF; Tzimas MN; Breton JJ; Chabot-Fletcher M; Underwood DC; Hay DW; Kingsbury WD; Chambers PA; Pendrak I; Jakas DR; Sathe GM; Van Horn S; Daines RA; Griswold DE
    Prostaglandins Leukot Essent Fatty Acids; 1999 Jul; 61(1):55-64. PubMed ID: 10477044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis.
    Konstan MW; Döring G; Heltshe SL; Lands LC; Hilliard KA; Koker P; Bhattacharya S; Staab A; Hamilton A;
    J Cyst Fibros; 2014 Mar; 13(2):148-55. PubMed ID: 24440167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of LY293111Na, a leukotriene B4 receptor antagonist, on the pulmonary neutrophilia and CD11b expression caused by inhalation of a leukotriene B4 aerosol in rhesus monkeys.
    Allen DL; Hoffman WP; Marder P; Matchett MR; Leiter PA; Abbott DL; Wolff RK
    J Pharmacol Exp Ther; 1996 Apr; 277(1):341-9. PubMed ID: 8613940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.
    Goodnow RA; Hicks A; Sidduri A; Kowalczyk A; Dominique R; Qiao Q; Lou JP; Gillespie P; Fotouhi N; Tilley J; Cohen N; Choudhry S; Cavallo G; Tannu SA; Ventre JD; Lavelle D; Tare NS; Oh H; Lamb M; Kurylko G; Hamid R; Wright MB; Pamidimukkala A; Egan T; Gubler U; Hoffman AF; Wei X; Li YL; O'Neil J; Marcano R; Pozzani K; Molinaro T; Santiago J; Singer L; Hargaden M; Moore D; Catala AR; Chao LC; Hermann G; Venkat R; Mancebo H; Renzetti LM
    J Med Chem; 2010 May; 53(9):3502-16. PubMed ID: 20380377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukotriene B4 mediates p47phox phosphorylation and membrane translocation in polyunsaturated fatty acid-stimulated neutrophils.
    Serezani CH; Aronoff DM; Jancar S; Peters-Golden M
    J Leukoc Biol; 2005 Oct; 78(4):976-84. PubMed ID: 16006535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ONO-LB-457: a novel and orally active leukotriene B4 receptor antagonist.
    Kishikawa K; Matsunaga N; Maruyama T; Seo R; Toda M; Miyamoto T; Kawasaki A
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():407-10. PubMed ID: 1847777
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro and in vivo activities of leukotriene B4-loaded biodegradable microspheres.
    Nicolete R; Lima Kde M; Júnior JM; Baruffi MD; de Medeiros AI; Bentley MV; Silva CL; Faccioli LH
    Prostaglandins Other Lipid Mediat; 2007 Feb; 83(1-2):121-9. PubMed ID: 17259078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the leukotriene B4 receptor antagonist SC-41930 on colonic inflammation in rat, guinea pig and rabbit.
    Fretland DJ; Widomski D; Tsai BS; Zemaitis JM; Levin S; Djuric SW; Shone RL; Gaginella TS
    J Pharmacol Exp Ther; 1990 Nov; 255(2):572-6. PubMed ID: 2173749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.